Compare Recursion Pharmaceuticals Inc (RXRX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Skyworks Solutions Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Skyworks Solutions Inc trades at $76.18 (market cap $11.34B). The key difference: Skyworks Solutions Inc is far larger — about 6.1× Recursion Pharmaceuticals Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SWKS | |
|---|---|---|
Market Cap | $1.86B | $11.34B |
Sector | Health | Technology |
52-Week High | $6.79 | $83.40 |
52-Week Low | $2.84 | $52.50 |
Enterprise Value | $1.38B | $11.22B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Skyworks Solutions (SWKS) trades at $75.38, up 1.84% with bullish technical signals from moving averages. The stock shows strong earnings momentum with three consecutive quarterly beats but faces revenue contraction from $5.5B in 2022 to $4.1B in 2025. Analyst consensus remains positive with 58% buy ratings, though the current price exceeds the $66.44 consensus target. Recent institutional buying and conference participation indicate continued market interest despite ongoing revenue challenges.
The outlook remains cautiously optimistic with AI data center growth providing upside potential, but declining revenue and margin compression present headwinds. Key risks include ongoing fiduciary investigations and competitive pressures in the semiconductor sector. The stock's elevated P/E ratio of 39 requires sustained earnings growth to justify current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
